Search
+
    SEARCHED FOR:

    STRIDES PHARMA EIR

    Strides Pharma Science shares jump 9% after USFDA EIR for Bengaluru facility

    Strides Pharma Science shares rise sharply on Thursday after the USFDA issued an Establishment Inspection Report (EIR) for its Bengaluru facility, concluding a recent cGMP inspection. The inspection ended with five observations, which the company addressed through corrective actions. The regulatory closure offers relief after the stock’s recent weakness.

    Strides Pharma's Chestnut Ridge unit in New York classified as voluntary action indicated by USFDA

    Strides Pharma Science announced its US subsidiary, Strides Pharma Inc, has received a Voluntary Action Indicated classification from the USFDA. This follows an inspection of its formulations unit in Chestnut Ridge, New York. The inspection covered Good Manufacturing Practices and drug-device combination capabilities. The facility supports the US market with various product types.

    Stelis Biopharma receives establishment inspection report from USFDA

    This follows the abbreviated quality system inspection technique drug pre-approval on-site inspection specifically conducted by the US Food and Drug Administration (USFDA) for the drug-device combination products that are to be manufactured and commercialised at the site for the partner products by Stelis, it said in a regulatory filing.

    USFDA clears four Indian manufacturing plants in 10 days

    India’s leading drug companies have had their manufacturing facilities cleared in the last 10 days by the US Food and Drug Administration (USFDA), a decision that comes at a time when supply-chain disruptions due to the Covid-19 pandemic are causing drug shortages across the world.

    Market Movers: Bajaj Fin, HDFC twins bleed; NIA surges; 219 stocks flash ‘buy’ signals

    HDFC twins were the two biggest negative contributors to Sensex’s fall. Both together shed over 600 points.

    Hold Strides Pharma, target price Rs 357: Geojit

    The move to front end sales and systematic product launches in the US will be key triggers for the company in the future.

    The Economic Times
    BACK TO TOP
    Advertisement